GL Pharm Tech Corp. (204840.KQ)
- Previous Close
1,185.00 - Open
1,219.00 - Bid --
- Ask --
- Day's Range
1,190.00 - 1,325.00 - 52 Week Range
705.00 - 1,830.00 - Volume
617,803 - Avg. Volume
502,883 - Market Cap (intraday)
47.235B - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas. In addition, the company engages in developing new molecule entity pipeline products for dry eye disease. Further, it provides Cabalin CR extended-release tablet and Jample Ibufen syrup for the nervous system and sensory organs; Gisoren tablets for individual organs, digestive system, and peptic ulcer drugs; and Genstring Troki for treating individual organs and digestive system, as well as oral use. GL Pharm Tech Corp. was founded in 2002 and is headquartered in Seongnam-si, South Korea.
www.glpt.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Related News
Performance Overview: 204840.KQ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 204840.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 204840.KQ
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-14.40%
Return on Assets (ttm)
-5.00%
Return on Equity (ttm)
-26.42%
Revenue (ttm)
26.03B
Net Income Avi to Common (ttm)
-3.75B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
4.14B
Total Debt/Equity (mrq)
144.80%
Levered Free Cash Flow (ttm)
-2.67B
Company Insights: 204840.KQ
204840.KQ does not have Company Insights